设定较高的非劣效性阈值：美沙拉嗪与布地奈德治疗克罗恩病 - Suppr

Suppr

超能文献

Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease.

作者信息

Levesque Barrett G, Sandborn William J

机构信息

Center for Digestive Diseases Mayo Clinic Rochester, Minnesota, USA.

出版信息

Inflamm Bowel Dis. 2012 Apr;18(4):795-6. doi: 10.1002/ibd.21813. Epub 2011 Jul 7.

DOI:10.1002/ibd.21813

PMID:21739537

Abstract

摘要

相似文献

Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease.设定较高的非劣效性阈值：美沙拉嗪与布地奈德治疗克罗恩病

Inflamm Bowel Dis. 2012 Apr;18(4):795-6. doi: 10.1002/ibd.21813. Epub 2011 Jul 7.

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.布地奈德 9 毫克在轻至中度活动期克罗恩病患者中的疗效至少与美沙拉嗪 4.5 克相当。

Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.布地奈德与美沙拉嗪治疗活动期克罗恩病的比较。国际布地奈德-美沙拉嗪研究组。

N Engl J Med. 1998 Aug 6;339(6):370-4. doi: 10.1056/NEJM199808063390603.

Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?轻至中度克罗恩病的初始治疗：美沙拉嗪还是布地奈德？

Rev Gastroenterol Disord. 2002;2 Suppl 2:S9-15.

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.布地奈德与美沙拉嗪用于对其他免疫调节剂不耐受的激素依赖型克罗恩病患者维持缓解的疗效比较

Clin Gastroenterol Hepatol. 2003 Mar;1(2):122-8. doi: 10.1053/cgh.2003.50015.

Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.布地奈德和美沙拉嗪治疗活动性克罗恩病：对生活质量影响的比较

Am J Gastroenterol. 2002 Mar;97(3):649-53. doi: 10.1111/j.1572-0241.2002.05544.x.

[Drug treatment of Crohn's disease].[克罗恩病的药物治疗]

Ned Tijdschr Geneeskd. 1998 May 23;142(21):1191-5.

Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.轻度至中度克罗恩病的药物治疗：诱导和维持缓解的循证治疗方案

Aliment Pharmacol Ther. 2007 Oct 1;26(7):987-1003. doi: 10.1111/j.1365-2036.2007.03455.x.

Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.美沙拉嗪胶囊（颇得斯安）用于克罗恩病的长期管理。颇得斯安克罗恩病同情用药研究组。

Am J Gastroenterol. 1993 Sep;88(9):1343-51.

A comparison of budesonide with prednisolone for active Crohn's disease.布地奈德与泼尼松龙治疗活动期克罗恩病的比较。

N Engl J Med. 1994 Sep 29;331(13):842-5. doi: 10.1056/NEJM199409293311304.

引用本文的文献

Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration.布地奈德用于诱导和维持克罗恩病缓解：Cochrane协作网的系统评价和荟萃分析

J Can Assoc Gastroenterol. 2018 Dec;1(4):159-173. doi: 10.1093/jcag/gwy018. Epub 2018 May 24.

Aminosalicylates for induction of remission or response in Crohn's disease.用于诱导克罗恩病缓解或反应的氨基水杨酸盐。

Cochrane Database Syst Rev. 2016 Jul 3;7(7):CD008870. doi: 10.1002/14651858.CD008870.pub2.

Budesonide for induction of remission in Crohn's disease.布地奈德用于诱导克罗恩病缓解

Cochrane Database Syst Rev. 2015 Jun 3;2015(6):CD000296. doi: 10.1002/14651858.CD000296.pub4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验